跳至主要内容
临床试验/NCT07246642
NCT07246642尚未招募4 期

Randomized Controlled Trial of Intracorporal Local Anesthesia vs Saline Prior to Placement of Inflatable Penile Prosthesis Placement

Wake Forest University Health Sciences2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年9月1日最近更新:
干预措施

试验速览

阶段
4 期
状态
尚未招募
入组人数
100
试验地点
2
主要终点
Visual Analogue Scale (VAS) Scores

研究概览

简要总结

The inflatable penile prosthesis (IPP) is the gold standard for surgical management of erectile dysfunction (ED) and there is no consensus on the best postoperative pain management regimen. In the wake of the opioid epidemic, postoperative pain management is heavily scrutinized. The National Institute of Health estimated over 81,000 individuals died following overdose of any opioids in 2022 alone; of these, over 14,000 deaths were linked to prescription opioids. Thus, strategies to minimize postoperative pain should not only improve patient experience but also lessen the need to escalate to opioid usage.

详细描述

It would be ideal to create an effective and easily reproducible approach to pain prevention and pain management in men undergoing IPP placement. One highly appealing target would be intracavernosal administration, as there would be no ambiguity regarding delivery of agent at the time of surgery. Thus far, no prospective randomized controlled trials have explored the efficacy of intracavernosal administration of local anesthetic for pain management.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

盲法说明

double blinding - the patients and the interviewing individuals

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Any patient undergoing primary three-piece inflatable penile prosthesis (IPP) placement at Lexington Medical Center

排除标准

  • Patients undergoing revision and/or secondary IPP placement
  • Patients taking prescribed narcotic medications at the time of IPP surgery
  • Patients undergoing concomitant Peyronie's Disease surgery (modeling, plication, grafting) at the time of IPP surgery
  • Patients with liver and/or renal disease

研究组 & 干预措施

Exparel/bupivacaine mixture Arm

Experimental

10cc Exparel/bupivacaine mixture will be injected into each corporal body (left and right for a total of 20cc)

干预措施: Exparel/bupivacaine mixture (Drug)

Control Saline Arm

No Intervention

10cc of normal saline will be injected into each corporal body (left and right for a total of 20cc)

结局指标

主要结局

Visual Analogue Scale (VAS) Scores

时间窗: Hour 24

VAS scores range from 0 to 100, with 0 representing no pain or the least desirable state and 100 representing the worst possible pain or the most desirable state. The "score" is the distance in millimeters from the "no pain" end of the 100mm line to the point where the person marks their pain level. Lower scores (0-4mm) indicate no pain, while higher scores (75-100mm) indicate severe pain.

Visual Analogue Scale (VAS) Scores

时间窗: Hour 1

VAS scores range from 0 to 100, with 0 representing no pain or the least desirable state and 100 representing the worst possible pain or the most desirable state. The "score" is the distance in millimeters from the "no pain" end of the 100mm line to the point where the person marks their pain level. Lower scores (0-4mm) indicate no pain, while higher scores (75-100mm) indicate severe pain.

Visual Analogue Scale (VAS) Scores

时间窗: Hour 4

VAS scores range from 0 to 100, with 0 representing no pain or the least desirable state and 100 representing the worst possible pain or the most desirable state. The "score" is the distance in millimeters from the "no pain" end of the 100mm line to the point where the person marks their pain level. Lower scores (0-4mm) indicate no pain, while higher scores (75-100mm) indicate severe pain.

次要结局

  • Cumulative Morphine milligram equivalents (MME)(Day 2)
  • Number of calls, messages, or visits to clinic(Day 30)
  • Number of Complications(Day 30)
  • Number of Other Complications(Day 30)
  • Serum bupivacaine levels(Hours 1 and 24)
  • Amount of tramadol usage(Hour 24)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验